VP, Corporate Communication and Investor Relations
Lucie is appointed on March 27 as Chief Financial Officer, responsible for all aspects of the Company’s financial strategy, management and operations to ensure efficient delivery of Transgene’s innovative immunotherapy pipeline. Since 2016, Lucie has served as Director Corporate Communications and Investor Relations, reporting to the CEO and joins the Executive Comity in October 2023 as VP, Corporate Communication and Investor Relations. Specialist in financial communications and press relations, Lucie came with over 10 years’ experience in communications agencies. She spent 3 years as a financial communications consultant at Ogilvy PR (2006 to 2008) before joining Citigate Dewe Rogerson (2009-2016). Her strategic contribution helped to ensure the smooth execution of four successful securities transactions, as well as multiple scientific, clinical and corporate announcements. Within the Paris office, she has also created a franchise dedicated to biotech companies, combining the sector expertise of the London subsidiary with her perfect knowledge of the French financial ecosystem.
She is a graduate of Paris Institute of Political Studies (Sciences Po), with a master’s degree in communication with a specialization in finance.
